Can FDG-PET Improve the Staging of Head and Neck Cancer?

We are very close to answering this question, but need your help!

By enrolling 75 more cases to the ACRIN 6685 trial: *FDG-PET/CT Staging of Head and Neck Cancer and the Impact on N0 Neck Surgical Treatment*, we will gain valuable information for improving patient care.

**Patient population:** Patients with newly diagnosed head and neck squamous cell carcinoma being considered for surgical resection, with at least one side of the neck planned for dissection clinically N0, and at risk for occult metastasis.

**Questions?**

Contact ACRIN 6685 Principal Investigator Brendan C. Stack, Jr., MD
501-773-4327 • BStack@uams.edu • www.acrin.org/6685_protocol.aspx

---

**ALABAMA**
University of Alabama-Birmingham

**ARKANSAS**
University of Arkansas Medical Center

**CALIFORNIA**
University of Southern California

**FLORIDA**
University of Florida, Jacksonville

**ILLINOIS**
Clinical Radiologists, S.C.
Simmons Cancer Institute at Southern Illinois University School of Medicine

**LOUISIANA**
Biomedical Research Foundation of NW Louisiana PET Imaging Center

**MARYLAND**
Johns Hopkins University

**MISSISSIPPI**
The University of Mississippi Medical Center

**MINNESOTA**
Mayo Clinic

**MISSOURI**
Washington University Cancer Research for the Ozarks

**NEW YORK**
Weill Cornell Medical College

**NORTH CAROLINA**
Wake Forest University School of Medicine

**OKLAHOMA**
University of Oklahoma Health Sciences

**PENNSYLVANIA**
Fox Chase Cancer Center
Thomas Jefferson University Hospital of the University of Pennsylvania

**WASHINGTON**
University of Washington

**INTERNATIONAL SITE**
**CHINA**
Peking Union Medical College Hospital